110030 ⎘
dsDNA viruses; Details; Poxviridae; Orthopoxvirus, e.g. vaccinia virus, variola Demonstrated effect
USE OF DR-18 AND ONCOLYTIC VACCINIA VIRUS IN PREPARATION OF ANTI-TUMOR DRUG
#2SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES
#3POXVIRUS-BASED VECTORS PRODUCED BY NATURAL OR SYNTHETIC DNA AND USES THEREOF
#4METHODS COMPRISING ONCOLYTIC VIRUSES EXPRESSING CD19T AND BISPECIFIC T CELL ENGAGERS
#5Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling
#6Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling
#7HUMAN METAPNEUMOVIRUS COMBINATION VACCINE
#8FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS
#9FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS
#10Combination Therapy for Treating Cancer with an Intravenous Administration of a Recombinant MVA and an Immune Checkpoint Antagonist or Agonist
#11IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPY
#12HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE
#13Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling
#14STRAIN DIS-DERIVED RECOMBINANT VACCINIA VIRUS HAVING NOVEL INFLUENZA VIRUS-DERIVED HEMAGGLUTININ PROTEIN GENE
#15DELIVERY OF SIALIDASE TO CANCER CELLS, IMMUNE CELLS AND THE TUMOR MICROENVIRONMENT
#16POXVIRUS-BASED VECTORS PRODUCED BY NATURAL OR SYNTHETIC DNA AND USES THEREOF
#17Immuno-Oncolytic Therapies
#18GENETICALLY ENGINEERED ONCOLYTIC VACCINIA VIRUSES AND METHODS OF USES THEREOF
#19ONCOLYTIC VACCINIA VIRUS
#20MODIFIED INTERLEUKIN 12 AND USE THEREOF IN PREPARING DRUGS FOR TREATING TUMOURS
#21USE OF MVA OR MVADELTAE3L AS IMMUNOTHERAPEUTIC AGENTS AGAINST SOLID TUMORS
#22ENGINEERED ONCOLYTIC VIRUSES EXPRESSING PD-L1 INHIBITORS AND USES THEREOF
#23HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
#24Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine
#25Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of an Immune Checkpoint Inhibitor
#26FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS
#27NOVEL GENETICALLY ENGINEERED VACCINIA VIRUSES
#28Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
#29Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
#30HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
#31ONCOLYTIC VIRUSES AND THERAPEUTIC MOLECULES
#32Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
#33Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine
#34Modified interleukin 12 and use thereof in preparing drugs for treating tumours
#35Nucleic acids encoding HLA-A24 agonist epitopes of MUC1-C oncoprotein
#36Compositions and methods for viral embolization
#37Whole expressed cell as antigen carrier, and use thereof in preparing vaccine or diagnostic agent, and screening monoclonal antibodies
#38Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
#39COMPOSITION AND USES THEREOF
#40IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPY
#41Genetically engineered vaccinia viruses
#42Recombinant modified vaccinia virus Ankara (MVA) Respiratory Syncytial Virus (RSV) vaccine
#43Virus-based expression vectors and uses thereof
#44METHODS AND COMPOSITIONS TO PRODUCE VACCINES AGAINST SMALLPOX IN PLANTS
#45Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
#46Mitogen-activated protein kinase-dependent recombinant vaccinia virus (MD-RVV) and use thereof
#47Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor
#48HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
#49Immuno-oncolytic therapies
#50Composition and uses thereof
#51Treatment and prevention of malaria
#52Immune modulation
#53ONCOLYTIC VIRUS ENCODING PD-1 BINDING AGENTS AND USES OF THE SAME
#54Composition comprising a colloidal synthetic bioresorbable vector and a viral vector
#55Modulation of immune responses by the poxviral K4 protein
#56Compositions, methods and uses for expression of enterobacterium-associated peptides
#57GENERATION OF A BROAD T-CELL RESPONSE IN HUMANS AGAINST HIV
#58MVA expressing modified HIV envelope, gag, and pol genes
#59ONCOLYTIC VACCINIA VIRUS CANCER THERAPY
#60Recombinant vectors based on the modified vaccinia ankara (mva) virus as vaccines against lieshmaniasis
#61USE OF RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) FOR THE TREATMENT OF TYPE 1 HYPERSENSITIVITY IN A LIVING ANIMAL INCLUDING HUMANS
#62Composition Comprising a Colloidal Synthetic Bioresorbable Vector and a Viral Vector
#63MVA expressing modified HIV envelope, gag, and pol genes
#64Custom vectors for treating and preventing pancreatic cancer
#65System for treating and preventing breast cancer